Citi Strategists Say Buy Dips, Don’t Chase Stock Rallies In 2024
(Bloomberg) -- There's no room for double-digit gains again. With less upside expected for global stocks this year than in 2023, Citigroup Inc. strategists say buy at times of weakness and don't chase rallies.
While the probability of broadening earnings growth and a soft landing for the global economy will support stocks in 2024, a rerating for valuations remain unlikely after last year's rally, strategists led by Beata Manthey wrote in a note on Friday.
The view is supported by expectations of about 8% upside for the MSCI All-Country World Index and 9% in earnings growth for 2024, “a conservative assumption in a Fed easing cycle,” they said.
“We would buy dips” while not necessarily chasing rallies, the strategists said.

After about 20% gains in 2023, the global benchmark is having a rockier start to the year with about 2% in losses in the first week. Investors have been more cautious after the euphoria of the past two months, while bond yields are rising again with traders trimming their expectations for interest rate cuts.
Citi's strategists see the economic backdrop as supportive for cyclical sectors and markets, preferring financials and industrials, as well as regions outside the US such as Europe ex-UK and emerging markets. Manthey has a neutral view on the US, with the region being less cyclical and already pricing in a soft landing.
She has been optimistic on Europe for most of 2023 , but sees the region still pricing a relatively bearish earnings outlook, even after the strong run.
“Cheap cyclical exposure keeps Europe well positioned for further market broadening and potential stimulus out of China,” she said.
More stories like this are available on bloomberg.com
©2024 Bloomberg L.P.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.